📰 Codexis Inc News
Page 8 - Codexis Inc News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Codexis Inc. Real-time updates on events, politics, business and more.
September 23, 2023
StockNews.com downgraded shares of Codexis (NASDAQ:CDXS – Free Report) from a hold rating to a sell rating in a report released on Tuesday morning. Several other analysts have also recently weighed in on CDXS. Stifel Nicolaus dropped their price objective on shares of Codexis from $9.00 to $5.00 and set a buy rating for the […]
September 18, 2023
REDWOOD CITY, Calif., Sept. 18, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced Stephen...
September 15, 2023
Codexis, Inc. (NASDAQ:CDXS – Get Free Report) insider Margaret Nell Fitzgerald purchased 11,834 shares of the stock in a transaction that occurred on Friday, September 8th. The stock was purchased at an average price of $1.70 per share, for a total transaction of $20,117.80. Following the acquisition, the insider now owns 81,420 shares in the […]
September 13, 2023
On September 11, 2023, Kevin Norrett, the COO of Codexis Inc (NASDAQ:CDXS), made a significant insider purchase of 9,000 shares of the company's stock.
September 12, 2023
Analysts’ upgrades for Monday, September 11th: Accenture (NYSE:ACN) was upgraded by analysts at StockNews.com from a hold rating to a buy rating. Antero Midstream (NYSE:AM) was upgraded by analysts at StockNews.com from a hold rating to a buy rating. Ascendis Pharma A/S (NASDAQ:ASND) was upgraded by analysts at StockNews.com from a sell rating to a […]
September 12, 2023
REDWOOD CITY, Calif., Sept. 12, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced the Company...
September 12, 2023
REDWOOD CITY, Calif., Sept. 12, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading enzyme engineering company, today announced the Company will attend the Cantor Global Healthcare Conference, being held
September 5, 2023
Benchmark restated their buy rating on shares of Codexis (NASDAQ:CDXS – Free Report) in a research note released on Friday, Benzinga reports. Benchmark currently has a $9.00 price objective on the biotechnology company’s stock. CDXS has been the subject of several other reports. HC Wainwright cut Codexis from a buy rating to a neutral rating […]
August 30, 2023
/PRNewswire/ -- The "Ligase Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2017 - 2027 Segmented By Product, By Source, By...
August 29, 2023
Wilmington, Delaware, United States, Aug. 29, 2023 (GLOBE NEWSWIRE) -- Transparency Market Research Inc. - The global market for enzymes was estimated to be worth US$ 7.7 billion in 2021. The market is anticipated to